ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...108109110111112113114115116117118...129130»
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Review, Journal:  Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. (Pubmed Central) -  Oct 15, 2020   
    Understanding the disease pathology responsible for the clinical manifestations of COVID-19 is imperative to identify the potential targets for drug development. This review explains the pathophysiology of COVID-19 and summarizes the potential treatment candidates, which can provide guidance in developing effective therapeutic strategies.
  • ||||||||||  ivermectin / Generic mfg.
    [VIRTUAL] Strongyloides stercoralis Larva in Esophageal Brushings: A Rare Cause of Esophageal Ulcerations in an HIV Patient () -  Oct 13, 2020 - Abstract #CAP2020CAP_618;    
    To the best of our knowledge, this is one of the very few cases reported in literature of esophageal ulcerations due to disseminated strongyloidiasis, diagnosed on cytology. This case reiterates the immense importance of keeping rare causes of esophagitis under consideration, in addition to viral and fungal etiologies, while examining the cytology and histologic biopsies of the esophagus in patients with HIV.
  • ||||||||||  Flagyl (metronidazole) / SLA
    [VIRTUAL] A CONFUSING CASE OF PNEUMONIA IN A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_1102;    
    The patient was empirically started on levofloxacin, metronidazole, intravenous (IV) trimethoprim-sulfamethoxazole and prednisone...She was subsequently started on IV ganciclovir... We describe a rare case of HIV related pneumonia caused by four different pathogens.
  • ||||||||||  prednisone / Generic mfg., ivermectin / Generic mfg., albendazole / Generic mfg.
    [VIRTUAL] HYPEREOSINOPHILIC SYNDROME: DEDUCING A CAUSE () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_784;    
    The evaluation of hypereosinophilia should be a multidisciplinary approach, involving specialists from infectious disease, rheumatology, pulmonology, hematology/oncology or allergy. An inaccurate diagnosis will be challenging to properly manage and potentially cure.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Nematocidal effect of Piper retrofractum Vahl on morphology and ultrastructure of Strongyloides stercoralis third-stage infective larvae. (Pubmed Central) -  Oct 10, 2020   
    Nematocidal bioassays revealed promising potential of PHE against S. stercoralis larvae, with an LC50 value of 0.059 mg/ml, while the reference drug ivermectin exerted higher efficacy, with an LC50 value of 0.020 µg/ml...Ultrastructural changes in the treated larvae, such as protruded lateral longitudinal grooves, loose muscle with vacuolation, dissociation between the hypodermis and cuticle and marked intracellular disorganization with vacuolation, were detected under transmission electron microscopy. The results of this study provide evidence that PHE is toxic against S. stercoralis and also a potential new alternative for anti-Strongyloides chemotherapy.
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Reduced gastrointestinal worm burden following long term parasite control improves body condition and fertility in beef cows. (Pubmed Central) -  Oct 10, 2020   
    On Day 0, fecal samples were collected from Angus cross cows (n = 1462) and they were assigned a body condition score (BCS: 1, emaciated; 9, Obese) and randomly divided into two groups (within location) to receive extended-release eprinomectin [PC-LT; n = 749; 50 mg/50 kg body weight (BW)] or pour-on ivermectin (PC-ST; n = 713; 25 mg/50 kg BW)...Lower FEG at Day 90 resulted in moderate to good body condition at Day 180 and cows with moderate to good body condition at Day 180 had higher P/BS. In conclusion, lower worm burden with long-term parasite control reduced FEG and improved BCS, P/AI and P/BS.
  • ||||||||||  ivermectin / Generic mfg.
    Clinical, Journal:  Ivermectin for causal malaria prophylaxis: A randomized controlled human infection trial. (Pubmed Central) -  Oct 8, 2020   
    Thus, further detailed studies are needed to determine the factors that reduce anthelmintic efficacy and increase anthelmintic resistance in donkeys. Ivermectin - at the dose used - has no clinically relevant activity against the pre-erythrocytic stages of P. falciparum.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Old and re-purposed drugs for the treatment of COVID-19. (Pubmed Central) -  Oct 8, 2020   
    In addition, tocilizumab might be considered as the supplementary treatment for COVID-19 patients with cytokine release syndrome. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.
  • ||||||||||  clarithromycin / Generic mfg., rifampicin / Generic mfg.
    Preclinical, Journal:  Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. (Pubmed Central) -  Oct 7, 2020   
    Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin...The imidazopyridine amine telacebec (Q203) exhibited high bactericidal activity whereas tedizolid (an oxazolidinone closely related to linezolid), selamectin and ivermectin (two avermectine compounds) and the benzothiazinone PBTZ169 were not active...Telacebec given twice a week in combination with a long-half-life compound, either rifapentine or bedaquiline, sterilized mouse footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented relapse during a period of 20 weeks after the end of treatment. These results are very promising for future intermittent oral regimens which would greatly simplify BU treatment in the field.
  • ||||||||||  Review, Journal:  Diagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19). (Pubmed Central) -  Oct 7, 2020   
    This review is aimed to collect and summarize a list of drugs used to treat COVID-19 for instance, dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide, and ivermectin. However, some of these drugs are not effective and suspended by the WHO (World Health Organization).